Medical/Pharmaceuticals

Tigermed Reports Full Year 2023 Results

HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2024-03-28 18:31

Sirnaomics Announces 2023 Annual Results

Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; st...

2024-03-28 17:09 247

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

ST. GALLEN, SWITZERLAND, March 28, 2024 /PRNewswire/ -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adul...

2024-03-28 15:00 493

TCI Gene Enhancing Malaysia's Preventive Healthcare In Collaboration With ALPRO Pharmacy

TAIPEI, March 28, 2024 /PRNewswire/ -- TCI Gene announced a strategic partnership with Alpro Pharmacy, a renowned chain pharmacy leader inMalaysia, to exclusively offer its genetic assessment services to Malaysians. TCI Gene and Alpro Pharmacy aims to provide Malaysians with better preventive hea...

2024-03-28 12:30 602

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

BEIJING and HONG KONG, March 28, 2024 /PRNewswire/ -- XtalPi, a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, today announced it will present a poster showcasing the latest a...

2024-03-28 09:05 793

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023

SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for ...

2024-03-28 07:01 1015

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During...

2024-03-27 22:30 1220

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * Healthy financial position with cash reserves of RMB 1,026.7 million as of December 31, 2023 and net loss narrowed by 57% from the past year * CStone established strategic collaborations with multip...

2024-03-27 22:00 1244

CARsgen Announced 2023 Annual Results

SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights * Z...

2024-03-27 20:50 1173

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitali...

2024-03-27 20:00 871

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place fromApril 9th to 11th, 2024, at the esteemed...

2024-03-27 20:00 678

Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project

TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...

2024-03-27 11:24 732

Innovative strides in medical-grade TPUs: ICP DAS-BMP to introduce groundbreaking solutions at CMEF and Medtec Japan

HSINCHU, March 27, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), Asia's leading medical TPU (thermoplastic polyurethane) manufacturer and supplier, will exhibit at the International Component Manufacturing and Design Show (ICMD, part of CMEF) and Medtec Japan inApril 2024. The company w...

2024-03-27 09:20 516

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...

2024-03-27 08:00 429

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Raul...

2024-03-27 06:00 186

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...

2024-03-27 05:59 316

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...

2024-03-27 01:16 510

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2024 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on co...

2024-03-26 23:58 266

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 727

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

2024-03-26 21:53 830
12345 ... 572

Week's Top Stories